1. Home
  2. GSHR vs TLSA Comparison

GSHR vs TLSA Comparison

Compare GSHR & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GSHR
  • TLSA
  • Stock Information
  • Founded
  • GSHR 2024
  • TLSA 2013
  • Country
  • GSHR United States
  • TLSA United Kingdom
  • Employees
  • GSHR N/A
  • TLSA N/A
  • Industry
  • GSHR
  • TLSA Biotechnology: Pharmaceutical Preparations
  • Sector
  • GSHR
  • TLSA Health Care
  • Exchange
  • GSHR NYSE
  • TLSA Nasdaq
  • Market Cap
  • GSHR 205.8M
  • TLSA 175.3M
  • IPO Year
  • GSHR 2025
  • TLSA 2000
  • Fundamental
  • Price
  • GSHR $10.06
  • TLSA $1.55
  • Analyst Decision
  • GSHR
  • TLSA
  • Analyst Count
  • GSHR 0
  • TLSA 0
  • Target Price
  • GSHR N/A
  • TLSA N/A
  • AVG Volume (30 Days)
  • GSHR 4.7K
  • TLSA 287.1K
  • Earning Date
  • GSHR 01-01-0001
  • TLSA 06-24-2025
  • Dividend Yield
  • GSHR N/A
  • TLSA N/A
  • EPS Growth
  • GSHR N/A
  • TLSA N/A
  • EPS
  • GSHR N/A
  • TLSA N/A
  • Revenue
  • GSHR N/A
  • TLSA N/A
  • Revenue This Year
  • GSHR N/A
  • TLSA N/A
  • Revenue Next Year
  • GSHR N/A
  • TLSA N/A
  • P/E Ratio
  • GSHR N/A
  • TLSA N/A
  • Revenue Growth
  • GSHR N/A
  • TLSA N/A
  • 52 Week Low
  • GSHR $9.97
  • TLSA $0.63
  • 52 Week High
  • GSHR $10.25
  • TLSA $1.91
  • Technical
  • Relative Strength Index (RSI)
  • GSHR N/A
  • TLSA 58.49
  • Support Level
  • GSHR N/A
  • TLSA $1.35
  • Resistance Level
  • GSHR N/A
  • TLSA $1.50
  • Average True Range (ATR)
  • GSHR 0.00
  • TLSA 0.10
  • MACD
  • GSHR 0.00
  • TLSA -0.00
  • Stochastic Oscillator
  • GSHR 0.00
  • TLSA 73.75

About GSHR GESHER ACQUISITION CORPORATION II ORD USD0.0001 CL A

Gesher Acquisition Corp II is a blank check company.

About TLSA Tiziana Life Sciences Ltd.

Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in the developing transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.

Share on Social Networks: